Abstract
Intrauterine stress exposure is associated with offspring health. DNA methylation (DNAm) is as a putative underlying mechanism, but large population-based studies reported limited associations between prenatal stress and DNAm. Recent research has shown that environmental factors in interaction with genetic variants are better predictors of DNAm than environment or genotype alone. We investigated whether interactions of maternal prenatal stress with genetic variants are associated with DNAm at birth. We examined 2,963 mother-child pairs from the population-based Generation R Study and Avon Longitudinal Study of Parents and Children, using a harmonized, comprehensive cumulative prenatal stress measure. We tested genome-wide genotype-by-prenatal stress interactions on epigenome-wide DNAm (GxEmodel), and models including only genetic variants (Gmodel) or prenatal stress (Emodel) as predictors. Follow-up analyses included Gene Ontology analyses and mediation analyses of prenatal alcohol intake, smoking, gestational age, and birth weight. We report two independent gene-by-prenatal-stress interactions on DNAm after multiple testing correction, including five genetic variants in CHD2 and ORC5, and two DNAm sites in EPPK1. By comparison, the Gmodel showed 691,202 associations and the Emodel showed three associations in genes AHRR, GFI1, and MYO1G, which could largely explained by prenatal smoking. Genes linked to suggestive GxEmodel results were often involved in neuronal development. Our results provide some support of interaction of prenatal stress with the child’s genome on DNAm of genes related to neuronal development. These results do not confirm the notion that gene-by-environment interaction models show more associations with DNAm compared to genes or the environment studied in isolation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The general design of The Generation R Study was made possible by financial support from Erasmus MC, Rotterdam, Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMW), the Netherlands Organization for Scientific Research (NWO), the Ministry of Health, Welfare and Sport and the Ministry of Youth and Families. High performance computing for data analysis was provided by the Dutch Organization for Scientific Research (NWO 2021.042, "Snellius" www.surf.nl).
The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. Genomewide genotyping data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. DNA methylation data generation was funded by the Biotechnology and Biological Sciences Research Council (BBSRC; grant numbers BBI025751/1 and BB/I025263/1) and the Medical Research Council (MRC; grand numbers MC_UU_12013/1, MC_UU_12013/2 and MC_UU_12013/8). A comprehensive lists of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). This publication is the work of the authors and Esther Walton will serve as guarantor for the contents of this paper.
The work of RHM, VB, SD, EW, CAMC and JFF is supported by the European Union's Horizon 2020 Research and Innovation Programme (RHM, VB, SD, EW, CAMC and JFF: EarlyCause, grant agreement No 848158; CAMC and JFF: STAGE; STAGE has received funding from the European Union's Horizon Europe Research and Innovation Programme under grant agreement no. 101137146. UK participants in Horizon Europe Project STAGE are supported by UKRI grant numbers 10112787 (Beta Technology), 10099041 (University of Bristol) and 10109957 (Imperial College London)). CAMC is also supported by the European Union's HorizonEurope Research and Innovation Programme (FAMILY, grant agreement No 101057529; HappyMums, grant agreement No 101057390) and the European Research Council (TEMPO; grant agreement No 101039672). EW also received funding from UK Research and Innovation (UKRI) under the UK government's Horizon Europe / ERC Frontier Research Guarantee [BrainHealth, grant number EP/Y015037/1]. This research was conducted while CAMC was a Hevolution/AFAR New Investigator Awardee in Aging Biology and Geroscience Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Generation R Study is conducted in accordance with the World Medical Association Declaration of Helsinki and has been approved by the Medical Ethics Committee of Erasmus MC, Rotterdam. Informed consent was obtained for all participants. Ethical approval for the ALSPAC study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from the Generation R Study are available upon reasonable request to the director of the Generation R Study (generationr{at}erasmusmc.nl), subject to local, national and European rules and regulations. ALSPAC data access is through a system of managed open access. The ALSPAC access policy (http://www.bristol.ac.uk/media-library/sites/alspac/documents/researchers/data-access/ALSPAC_Access_Policy.pdf) describes the process of accessing the data and samples in detail, and outlines the costs associated with doing so.
